Hepion Pharmaceuticals Future Growth

Future criteria checks 0/6

Hepion Pharmaceuticals's earnings are forecast to decline at 23.5% per annum while its annual revenue is expected to grow at 90.4% per year. EPS is expected to grow by 9.2% per annum.

Key information

-23.5%

Earnings growth rate

9.2%

EPS growth rate

Pharmaceuticals earnings growth	21.2%
Revenue growth rate	90.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	23 May 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:336 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	N/A	-82	-73	N/A	2
12/31/2024	N/A	-62	-45	N/A	2
12/31/2023	N/A	-51	-10	N/A	2
3/31/2023	N/A	-52	-33	-33	N/A
12/31/2022	N/A	-45	-35	-35	N/A
9/30/2022	N/A	-45	-38	-38	N/A
6/30/2022	N/A	-46	-36	-36	N/A
3/31/2022	N/A	-34	-34	-34	N/A
12/31/2021	N/A	-33	-31	-31	N/A
9/30/2021	N/A	-28	-29	-28	N/A
6/30/2021	N/A	-25	-21	-21	N/A
3/31/2021	N/A	-22	-19	-19	N/A
12/31/2020	N/A	-20	-16	-16	N/A
9/30/2020	N/A	-18	-14	-14	N/A
6/30/2020	N/A	-13	-12	-12	N/A
3/31/2020	N/A	-15	-10	-10	N/A
12/31/2019	N/A	-12	-8	-8	N/A
9/30/2019	N/A	-12	-10	-10	N/A
6/30/2019	N/A	-20	-12	-12	N/A
3/31/2019	N/A	-17	-14	-14	N/A
12/31/2018	N/A	-18	-16	-16	N/A
9/30/2018	N/A	-17	-13	-13	N/A
6/30/2018	N/A	-14	-15	-15	N/A
3/31/2018	N/A	-8	-16	-16	N/A
12/31/2017	N/A	-13	-18	-18	N/A
9/30/2017	N/A	-16	-20	-20	N/A
6/30/2017	N/A	-15	-19	-19	N/A
3/31/2017	N/A	-22	-19	-19	N/A
12/31/2016	N/A	-18	N/A	-18	N/A
9/30/2016	N/A	-17	N/A	-18	N/A
6/30/2016	N/A	-17	N/A	-17	N/A
3/31/2016	N/A	-17	N/A	-16	N/A
12/31/2015	N/A	-21	N/A	-15	N/A
9/30/2015	N/A	-26	N/A	-11	N/A
6/30/2015	N/A	-22	N/A	-10	N/A
3/31/2015	N/A	-12	N/A	-6	N/A
12/31/2014	N/A	-14	N/A	-4	N/A
9/30/2014	N/A	-7	N/A	-2	N/A
6/30/2014	N/A	-5	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 336 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 336 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 336 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 336 is forecast to have no revenue next year.

High Growth Revenue: 336 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 336's Return on Equity is forecast to be high in 3 years time

Hepion Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Hepion Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Stockholder's Deficit

Hepion Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) in a reverse merger transaction valued at an implied equity value of approximately $58.5 million.

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease

Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice

Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding

Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial

High number of new directors

Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma

Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Hepion Pharmaceuticals Receives 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Publication of Phase 2A 'Ambition' Clinical Trial Results

Hepion Pharmaceuticals, Inc. Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022

Hepion Pharmaceuticals, Inc. Announces Board Changes

Hepion Pharmaceuticals, Inc. Appoints Dr. Launa J. Aspeslet as Chief Operating Officer

Hepion Pharmaceuticals Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard from Nasdaq

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2022

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals Appoints Eddie C. Cheung to Lead the Company’s Strategic Medical Affairs in Asia

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer

Hepion Pharmaceuticals, Inc Announces Additional Efficacy Data from Its Phase 2A Ambition Clinical Trial

Hepion Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 2A ‘Ambition’ Nash Trial and Achieve All Primary Endpoints

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2A 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $88.4 million.

Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Hepion Pharmaceuticals Terminated the At Market Issuance Sales Agreement with B. Riley FBR, Inc

New 90-day low: €2.22

Hepion Pharmaceuticals, Inc.'s Data Safety Monitoring Board Recommends Continuation of Phase 2A 'Ambition' Clinical Trial for Treatment of Advanced Nash

New 90-day low: €2.44

Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development

Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases

New 90-day high - €3.76

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies